To explicitly show the effect of tumor-specific Cyp51 inhibition on MSS CRC progression, we studied the in vivo growth of the abovementioned Cyp51-KO CT26 cells that had reduced secretion of distal cholesterol precursors and impaired induction of Th17 polarization (Fig. 4C–F). The gene discussed is CYP51A1; the disease is neoplasm.